Liver metastases of malignant melanoma – utility of resection or radiofrequency ablation
Authors:
V. Třeška 1; T. Skalický 1; Inka Třešková 2
; V. Liška 1; J. Fichtl 1; J. Brůha 1; E. Korčáková 3
Authors place of work:
Chirurgická klinika LF Univerzity Karlovy a FN v Plzni, přednosta: prof. MUDr. V. Třeška, DrSc.
1; Oddělení plastické chirurgie FN v Plzni, primář: MUDr. V. Bursa
2; Klinika zobrazovacích metod LF Univerzity Karlovy a FN v Plzni, přednosta: prof. MUDr. B. Kreuzberg, CSc.
3
Published in the journal:
Rozhl. Chir., 2016, roč. 95, č. 10, s. 350-353.
Category:
Original articles
Summary
Introduction:
Incidence of cutaneous and uveal forms of malignant melanoma (MM) has increased significantly in the population in the last years. Biological behavior of both these forms of MM is different and is associated with the development of liver metastases. The prognosis of patients with MM liver metastases is generally poor. The authors seek to consider the sense and the possibilities of surgical treatment of MM liver metastases.
Method:
Seven patients with liver metastases of MM were operated on in the Hepatobiliary Center of the Department of Surgery, University Hospital in Pilsen during the last ten years. Four patients suffered from the uveal and three from the cutaneous form of MM. Mean age of the patients was 58.8 years. R0 liver resection was performed in 3, and radiofrequency ablation in 1 patient. In the remaining 3 patients the operation finished by exploratory laparotomy due to tumor progression.
Results:
Two patients died in the interval of 6 and 25 months after liver surgery for tumor dissemination. Two patients continue to show disease free survival, currently of 22 and 28 months.
Conclusion:
Liver metastases of MM have a very poor prognosis. Surgical treatment indicated by the multidisciplinary team provides, together with further multimodal treatment, a chance for long-term survival and its indication is justified in selected patients.
Key words:
malignant melanoma – liver metastases – surgical treatment
Zdroje
1. Linos E, Swetter SM, Cockburn MG, et al. Increasing burden of melanoma in the United States. Invest Dermatol 2009;129:1666−74.
2. Třešková I, Pizinger K, Kacerovská D, et al. Obtížná diferenciální diagnostika maligního melanomu – kazuistiky. Rozhl Chir 2013;92:654−8.
3. Doussot A, Nardin C, Takaki H, et al. Liver resection and ablation for metastatic melanoma: A single center experience. Surg Oncol 2015;111:962−8.
4. Zani S, Clary BM. A role for hepatic metastasectomy in stage IV melanoma and breast cancer: reestablishing the surgical modality. Oncology 2011;25:1158−64.
5. Algazi AP, Soon CW, Daud AI, et al. Treatment of cutaneous melanoma: current approaches and future prospects. Cancer Manag Res 2010;2:197−211.
6. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507−16.
7. Aubin JM, Rekman J, Vandenbroucke-Menu F. Systematic review and meta-analysis of liver resection for metastatic melanoma. Br J Surg 2013;100:1138−47.
8. Howard JH, Thompson JF, Mozzillo N, et al. Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol 2012;19:2547−55.
9. Wevers KP, Hoekstra HJ. Stage IV melanoma: Completely resectable patients are scarce. Ann Surg Oncol 2013; 20: 2352−6.
10. Faries MB, Leung A, Morton DL, et al. A 20-year experience of hepatic resection for melanoma: is there an expanding role? J Am Coll Surg 2014;219:62−8.
11. Karimkhani C, Gonzalez R, Dellavalle RP. A review of novel therapies for melanoma. Am J Clin Dermatol 2014;15:323−37.
12. Caralt M, Martí J, Cortés J, et al. Outcome of patients following hepatic resection for metastatic cutaneous and ocular melanoma. J Hepatobiliary Pancreat Sci 2011;18:268−75.
13. Pawlik TM, Zorzi D, Abdalla EK. Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease. Ann Surg Oncol 2006;13:712−20.
14. Ryu SW, Saw R, Scolyer RA. Liver resection for metastatic melanoma: equivalent survival for cutaneous and ocular primaries. J Surg Oncol 2013;108:129−35.
15. Aoyama T, Mastrangelo MJ, Berd D, et al. Protracted survival after resection of metastatic uveal melanoma. Cancer 2000;89:1561−8.
16. Crook TB, Jones OM, John TG, et al. Hepatic resection for malignant melanoma. Eur J Surg Oncol 2006;32:315−7.
17. Rose DM, Essner R, Hughes TM, et al. Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experience. Arch Surg 2001;136:950−5.
18. Sanki A, Scolyer RA, Thompson JF. Surgery for melanoma metastases of the gastrointestinal tract: indications and results. Eur J Surg Oncol 2009;35:313−9.
19. Caralt M, Marti J, Cortes J, et al. Outcome of patients following hepatic resection for metastatic cutaneous and ocular melanoma. J Hepatobiliary Pancreat Sci 2011;18:268−75.
20. Ryu SW, Saw R, Scolyer R, et al. Surgical management of liver metastasis from metastatic melanoma. HPB 2012;14; 159−60.
Štítky
Surgery Orthopaedics Trauma surgeryČlánok vyšiel v časopise
Perspectives in Surgery
2016 Číslo 10
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Metamizole in perioperative treatment in children under 14 years – results of a questionnaire survey from practice
Najčítanejšie v tomto čísle
- Myxofibrosarcoma in the abdominal cavity
- Total pancreatectomy for pancreatic malignancy - from history to the present day
- Complete mesocolic excision during right hemicolectomy
- Liver metastases of malignant melanoma – utility of resection or radiofrequency ablation